This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 5, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted
A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers

Condition Intervention Phase
Capsaicin Evoked Pain Heat Sensitivity Drug: AZD1386 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Single-Centre, Placebo-Controlled, Crossover Study to Investigate the Effects of a Single Oral Dose of AZD1386 on Intradermal Capsaicin Evoked Pain Symptoms and Heat Sensitivity in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • VAS, HPT [ Time Frame: Visit 2-4 ]

Secondary Outcome Measures:
  • eVAS, HPT, Laser Doppler imaging,WDT, Somedic allodynia [ Time Frame: Visit 2-4 ]
  • Vital signs, laboratory variables and adverse event each day throughout the study. paper printout ECG and/or digital ECG throughout the study. Pain evoked assessments visit 1-3 [ Time Frame: Visit 1-5 ]
  • Pharmacokinetics/Pharmacodynamics [ Time Frame: Visit 2-4 ]

Enrollment: 36
Study Start Date: January 2008
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
Drug: AZD1386
Oral solution fixed dose (95 mg given orally on two occasions)
Placebo Comparator: 2
36 subjects receiving a specified volume of placebo in a single dose.
Drug: Placebo
Oral solution fixed dose (95 mg given orally on two occasions)


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinical normal physical findings, including BP, pulse rate >45 bpm, ECG and laboratory assessments
  • Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg.
  • Non-fertile females

Exclusion Criteria:

  • History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.
  • History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the Investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00692146

Sponsors and Collaborators
Study Chair: Agneta Berg AstraZeneca R&D Södertälje
Principal Investigator: Ingemar Bylesjö AstraZeneca R&D CPU Karolinska University Hospital, Stockholm
  More Information

Responsible Party: Rolf Karlsten, MD, PhD Medical Science Director, AstraZeneca R&D Södertälje Identifier: NCT00692146     History of Changes
Other Study ID Numbers: D5090C00009
Study First Received: June 5, 2008
Last Updated: June 5, 2008

Keywords provided by AstraZeneca:
Proof of Mechanism
Capsaicin evoked pain

Additional relevant MeSH terms:
Immune System Diseases
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs processed this record on August 23, 2017